Toleranzia AB receives loan commitment of SEK 20 million
Toleranzia AB (“Toleranzia” or the “Company”) has signed an agreement with Flerie Invest AB including a loan commitment of SEK 20 million. The agreement, which has been signed on market terms, enters into force on May 1, 2024, and has a term of 12 months. The agreement runs without collateral and the interest rate is a maximum of SEK nine hundred and ninety thousand.
“We are in a very intense phase with a lot of ongoing activities in view of the start of the Phase I/IIa clinical trial of our lead drug candidate TOL2 in patients with myasthenia gravis. With this loan commitment, we strengthen the capital base to ensure reaching this milestone. In addition to the capital injection, we are very pleased with the confidence shown in us by our main shareholder, which adds significant strength and stability to the company’s operations”, comments Charlotte Fribert, CEO of Toleranzia.
For further information, please contact
Charlotte Fribert – CEO, Toleranzia AB
Tel: +46 763 19 98 98
Email: charlotte.fribert@toleranzia.com
About Toleranzia AB (publ)
Toleranzia AB (publ) develops drugs that utilize the immune system’s own power to treat autoimmune orphan diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, only reduce the symptoms. They have the potential to be the first long-acting or curative treatments that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia’s shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, CA@mangold.se, is the company’s Certified Adviser.